July 2019
Volume 60, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2019
Presentation Features for a Multinational Treatment Trial of Nonarteritic Anterior Ischemic Optic Neuropathy
Author Affiliations & Notes
  • Mark J Kupersmith
    Neurology / Ophthalmology, Icahn School of Medicine at Mount Sinai, New York, New York, United States
    New York Eye and Ear Infirmary, New York, New York, United States
  • Neil Miller
    Wilmer Institute of Johns Hopkins School of Medicine, Baltimore, Maryland, United States
  • Leonard A Levin
    McGill University, Quebec, Canada
  • Sharon Klier
    Quark Pharmaceutical, California, United States
  • Footnotes
    Commercial Relationships   Mark Kupersmith, Quark Pharmaceutical (C); Neil Miller, Quark Pharmaceutical (C); Leonard Levin, Quark Pharmaceutical (C); Sharon Klier, Quark Pharmaceutical (E)
  • Footnotes
    Support  Quark Pharmaceutical, Inc.
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 2261. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Mark J Kupersmith, Neil Miller, Leonard A Levin, Sharon Klier; Presentation Features for a Multinational Treatment Trial of Nonarteritic Anterior Ischemic Optic Neuropathy. Invest. Ophthalmol. Vis. Sci. 2019;60(9):2261.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose : Awareness of presenting features and systemic factors associated with acute non-arteritic anterior ischemic optic neuropathy (NAION) is based on data from one prospective treatment trial, with 258 participants and cases series. The Quark / NORDIC NAION treatment trial will recruit approximately 800 participants and the attributes for the first 400 subjects, enrolled from multiple sites in 8 countries, provides the largest prospective uniformly-collected dataset on this disorder.

Methods : We describe presentation data, for participants with acute symptomatic NAION enrolled in a double-masked randomized clinical trial, including comprehensive medical history, laboratory studies, EKG, ophthalmic evaluation including optical coherence tomography (OCT) and 24-2 threshold perimetry, using spot size III and spot size V.

Results : Of the first 400 enrollees (121 women, 279 men), with average age 61 years, 46% had hypertension, 24% diabetes, 46% hyperlipidemia, 25% cardiac disease, 2.5% ischemic brain disease (with wide variability by country). The fellow eye had prior NAION in 18%. Vision evaluations at screening and day 1 (mean separation 1.9 days) were similar, as visual acuity (r = 0.90) and the average fovea threshold of the visual field (r = 0.89) for each correlated (p = 0.01). OCT-measured retinal nerve fiber layer (RNFL) thickening mildly correlated with the average visual field threshold for spot III (r= 0.24) and spot V (r=0.27) but not with visual acuity.

Conclusions : These results confirm prior accounts showing the relevance of systemic disorders in NAION, but it appears that hyperlipidemia is more frequent and cerebrovascular disease less common than previously reported. Optic disc swelling, determined by RNFL thickening, correlates with visual field deficit but not loss of visual acuity.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.